CJC/IPA: A Research Overview of the CJC-1295 and Ipamorelin Reference Blend

CJC/IPA is a single-vial reference preparation containing two distinct, separately characterized research peptides: CJC-1295 (with the Drug Affinity Complex modification, CAS 863288-34-0) and Ipamorelin (CAS 170851-70-4), each specified at greater than or equal to 99% purity per component and supplied as a co-lyophilized white powder. The two peptides are not chemically bonded; they are physically combined so that a researcher reconstituting the vial obtains both molecules in a fixed nominal ratio. This matters for any honest description of the product: a blend is a mixture of independently defined reference standards, and its analytical identity is the sum of its parts rather than a novel single entity.

Because the constituents are unrelated in structure and mechanism, the most accurate way to characterize CJC/IPA is to characterize each component on its own terms and then describe why investigators co-formulate them. The remainder of this page does precisely that. For the full analytical specification of the combined vial — component masses, purity per component, formulation notes, and certificate-of-analysis methodology — see the separate CJC/IPA data sheet.

CJC-1295 is studied as a synthetic analog of growth-hormone-releasing hormone, built on the first 29 amino acids of native GHRH — the fragment commonly designated GRF(1-29). In published research models it acts at the GHRH receptor on pituitary somatotroph cells, where receptor engagement activates adenylate cyclase and raises intracellular cyclic AMP, a pathway associated in those models with the synthesis and pulsatile release of growth hormone. As a reference description, CJC-1295 is therefore positioned mechanistically as a GHRH-receptor agonist analog; this is research context describing what the molecule is studied to do in defined experimental systems, not a statement of any effect in humans.

A distinction that matters for any reference description is the form of CJC-1295. The compound is examined in two variants. The DAC form carries a Drug Affinity Complex lysine modification that, in studied models, covalently binds serum albumin and substantially extends the circulating half-life (reported on the order of roughly 6–8 days in those models). The no-DAC form — frequently labeled "Modified GRF 1-29" or "Mod GRF 1-29" — lacks that modification and is associated with a much shorter half-life (on the order of about 30 minutes). The two are not interchangeable in research terms, so a reference page must state which form a given material contains. The CJC/IPA blend described here contains the DAC form of CJC-1295.

Ipamorelin is studied as one of the first highly selective growth hormone secretagogues — a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, structurally derived from the GHRP-1 framework. In the research literature it is characterized as an agonist of the growth hormone secretagogue receptor (GHS-R), the same ghrelin-mimetic receptor pathway engaged by other GH-releasing peptides, expressed in the hypothalamus and pituitary. The principal research interest in Ipamorelin is its selectivity: in published in-vitro and animal models it is reported to stimulate growth hormone release with minimal associated effect on cortisol, prolactin, or ACTH, a profile that distinguishes it from older, less selective secretagogues such as GHRP-6. Potency data in those models describe an EC50 on the order of roughly 1.3 nmol/L in vitro (Raun et al., 1998; PMID 9849822).

As with CJC-1295, this is research context: it describes what Ipamorelin is studied to do at its receptor in laboratory systems, and it is not a description of any human or veterinary effect, dose, or application. A dedicated Ipamorelin research page is not yet published on this site.

The defensible, mechanistic rationale for pairing these two peptides is receptor complementarity. The components act on two separate receptor systems that, in published research models, converge on growth hormone release: CJC-1295 engages the GHRH receptor, while Ipamorelin engages the GHS-R / ghrelin-mimetic pathway. Because the two pathways are distinct, they are frequently studied together rather than as a claim about the blend's own efficacy — the interest is in how two independent inputs to the same downstream readout behave when present at once. Component-level literature has reported additive or greater-than-additive GH output when a GHRH analog and a GH secretagogue are applied together in such models, which is the standard scientific basis for co-formulating them as a reference pair.

This rationale is mechanistic and component-level only. There is no dedicated study of the specific CJC/IPA blend as a single entity, and no combined effect is claimed for the product. The pairing is described here to explain why two unrelated peptides appear in one reference vial — not to attribute any biological outcome, benefit, dose, or use to the mixture.

Both constituents of CJC/IPA are peptides supplied as a co-lyophilized powder, so they share the general handling profile of lyophilized peptide reference materials. Lyophilized peptides are typically hygroscopic and are generally most stable when kept dry, cold, and protected from light; reconstituted peptide solutions are usually less stable than the dry powder and are commonly aliquoted to avoid repeated freeze-thaw cycles. Because the blend contains two different molecules, any reconstitution and stability protocol should account for both — solvent compatibility, working concentration, and analytical confirmation are considerations for the mixture as a whole. These are general laboratory considerations stated as research-handling context, not instructions for preparing material for any use in humans or animals.

The specific reconstitution solvents, storage temperatures, aliquoting guidance, and stability notes for this particular blend are documented on the CJC/IPA storage and reconstitution guide. Storage and handling practice materially affect peptide integrity and therefore the reproducibility of any in-vitro research using the material, which is why a blend-specific guide is maintained separately from this overview.

Neither CJC-1295 nor Ipamorelin is an FDA-approved drug, and the CJC/IPA blend is not an approved drug, dietary ingredient, cosmetic, or article for human or veterinary use. The product is supplied strictly as a reference compound for in-vitro and laboratory research conducted by qualified investigators. Nothing on this page is a description of therapeutic effect, performance effect, dosing, or any benefit to a person or animal. Where research context is given for the individual components, it describes what specific molecules are studied to do at their receptors in defined laboratory and animal models — the actual ceiling of what that literature establishes — and it must not be read as guidance for use. Investigators are responsible for compliance with all applicable institutional, local, and national regulations governing the acquisition, handling, and use of research peptides.